James R. Dutton, PhD

Research Assistant Professor, Department of Genetics, Cell Biology and Development

James R. Dutton

Contact Info


Office Phone 612-626-2762

Office Address:
Stem Cell Institute
2-220 MTRF
2001 6th St SE
Minneapolis, MN 55455

Mailing Address:
Stem Cell Institute
2873B (Campus Delivery Code)
2001 6th St SE
Minneapolis, MN 55455

PhD, University of Wales (A Genetic and Biochemical Study of Microbial Phthalate Degradation), 1992

BSc, University of Cardiff (Microbiology with Genetics), 1988



Cell reprogramming, Induced Pluripotent cells

Professional Associations

  • iPS Cell Facility Coordinator, Stem Cell Institute, University of Minnesota, Minneapolis, 2008
  • Assistant Professor Stem Cell Institute, University of Minnesota, Minneapolis, USA, 2007
  • Research Coordinator, Prof. Slack group, Centre for Regenerative Medicine, University of Bath, UK, 2004-07
  • Research Associate, Department of Biology and Biochemistry, University of Bath, 1997-04
  • Research Associate, Department of Microbiology, University of Idaho, USA, 1993-97
  • Postdoctoral Researcher, Department of Microbiology, University of Idaho, USA, 1992-93


Research Summary/Interests

Cell Reprogramming

I am a developmental biologist interested in harnessing the ability of transcription factors to direct cell specification. My previous research involved all aspects of transcription factor function and regulation during body plan and organ development using model organisms (fungi, zebrafish, frogs and mice). In my current research I utilize knowledge of developmental biology to inform our reprogramming strategies to generate differentiated cells for clinical application. Currently we are applying this approach to directly reprogram liver cells to insulin expressing cells to treat diabetes and skin fibroblasts into oligodendrocyte progenitors to treat spinal cord injury. We have also developed the first transgenic mouse model to allow lineage tracing of Oct4 in both development and reprogramming. We are using this model to gain new insights into the mechanism of direct reprogramming during iPS cell generation.

Clinical application of Induced Pluripotent cellls
I also direct the activities of the Cell Reprogramming Core Facility at the University of Minnesota Stem Cell Institute. My reseach interests here also involve the clinical application of cell reprogramming. We are working to generate Induced Pluripotent Stem (iPS) cells suitable for clinical use and use iPS cells as a pluripotent intermediate to generate specifc differentiated cells for clinical transplant or modelling disease.


  • Hill CM, Banga A, Abrahante JE, Yuan C, Mutch LA, Janecek J, O'Brien T, Graham ML, Dutton JR (2017) Establishing a large animal model for in vivo reprogramming of bile duct cells into insulin secreting cells to treat diabetes. Human Gene Therapy. Clinical Development June 2017, 28(2): 87-95. PMID: 28363269
  • Geng Z, Walsh PJ, Truong V, Hill C, Ebeling M, Kapphahn RJ, Montezuma SR, Yuan C, Roehrich H, Ferrington DA, Dutton JR. (2017) Generation of retinal pigmented epithelium from iPSCs derived from the conjunctiva of donors with and without age related macular degeneration. PloS One. 12(3):e0173575.
    PMCID: PMC5345835
  • Parr, AM, Walsh P, Truong V, and Dutton JR (2016) cGMP-compliant expansion of human iPSC cultures as adherent monolayers. Methods in Molecular Biology 1357:221-9 PMID: 25863788
  • Terzic D, Maxon J, Krevitt L, DiBartolomeo C, Goyal T, Low W, Dutton JR*, Parr A* (*co-senior) (2016) Directed differentiation of oligodendrocyte progenitor cells from mouse induced pluripotent stem cells. Cell Transplantation 25(2):411-24PMID: 25955415
  • Greder LV, Post J and Dutton JR (2016) Using Oct4:MerCreMer Lineage tracing to monitor endogenous Oct4 expression during the reprogramming of fibroblasts into induced pluripotent cells. Methods in Molecular Biology 1357:97-110. PMID: 25687297
  • Maza I, Caspi I, Zviran A, Chomsky E, Rais Y, Viukov S, Geula S, Buensrostro J, Weinberger L, Krupalnik V, Hanna S, Zerbib M, Dutton JR, Greenleaf W, Massarwa R, Novershtern N, Hanna JH (2015) Transient acquisition of pluripotency during somatic cell transdifferentiation with iPSC reprogramming factors. Nature Biotechnology 33(7):769-74. PMCID: PMC4500825
  • Banga A, Greder LV, Dutton JR, Slack JMW. (2014) Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist. Gene Therapy. 21, 19-27. PMCID: PMC3880604
  • Ye L, Chang Y, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, Kaufman D, Ge Y, Zhang J (2014) Cardiac Repair in a Porcine Model of Acute Myocardial Infarction with Human Induced Pluripotent Stem Cell-Derived Cardiovascular Cells. Cell Stem Cell, 15, 6, 750–761
    PMCID: PMC4275050
  • Ye L, Zhang S, Greder L, Dutton JR, Keirstead SA, Lepley M, Zhang L, Kaufman D, Zhang J. (2013) Effective Cardiac Myocyte Differentiation of Human Induced Pluripotent Stem Cells Requires VEGF.PLoS ONE 8(1): e53764.
  • Banga A, Akinci E, Greder L, Dutton JR, Slack JMW. (2012) In vivo reprogramming of Sox9 positive cells in the liver to insulin-secreting ducts. Proc Natl Acad Sci U S A. 109 (38) 15336-41
  • Greder L, Gupta S, Li S, Abedin M, Sajini A, Segal Y, Slack, JMW, Dutton JR. (2012) Analysis of Endogenous Oct4 Activation during iPS Cell Reprogramming Using an Inducible Oct4 Lineage Label.Stem Cells 30 (11) 2596-601
  • Sajini A, Greder L, Dutton JR, Slack JMW. (2012) Loss of Oct4 expression during the development of murine embryoid bodies. Developmental Biology 371, 170-179.
  • Kudva Y, Ohmine S, Greder L, Dutton JR, Armstrong A, De Lamo G, Khan Y, Thatava T, Hasegawa M, Fusaki N, Slack JMW, Ikeda Y. (2012) Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Translational Medicine 1 (6) 451- 461
  • Akinci E, Banga A, Greder LV, Dutton JR, Slack JMW. (2012) Reprogramming pancreatic exocrine cells to a beta cell character using Pdx1, Ngn3 and MafA. Biochem J. 442 (3) 539-50
  • Watanabe S, Hirai H, Tastad C, Verma M, Asakura Y, Keller C, Dutton JR, Asakura A. (2011) MyoD gene suppression by Oct4 is required for reprogramming in myoblasts to produce iPS cells. Stem Cells. 29 (3) 505-16
  • Coad RA, Dutton JR, Tosh D, Slack JMW. (2009) Inhibition of Hes1 activity in gall bladder epithelial cells promotes insulin expression and glucose responsiveness. Biochem Cell Biol. 87(6) 975-87.
  • Dutton JR, Daughters RS, Chen Y, O'Neill KE, Slack JMW. (2009) Use of adenovirus for ectopic gene expression in Xenopus. Dev Dyn. 238 (6) 1412-21.
  • Dutton JR, Antonellis A, Carney TJ, Rodrigues FS, Pavan WJ, Ward A, Kelsh RN. (2008) An evolutionarily conserved intronic region controls the spatiotemporal expression of the transcription factor Sox10. BMC Dev Biol. 26, (8) 105
  • Dutton JR., Chillingworth, N, Eberhard D, Brannon, CR, Hornsey MA, Tosh D, Slack JMW. (2007) Beta Cells occur naturally in extrahepatic bile ducts of mice. J Cell Sci 120 (2) 239-245
  • Lahiri D, Dutton JR, Duarte A, Moorwood K, Graham CF, Ward A. (2007). Nephropathy and defective spermatogenesis in mice transgenic for a single isoform of the Wilms' tumour suppressor protein (WT1-KTS) together with one disrupted Wt1 allele. Mol. Reprod. Dev. 74, (3) 300-11
  • Dutton JR, Lahiri D, Ward A (2006) Different isoforms of the Wilm's tumour protein WT1 have distinct patterns of distribution and trafficking within the nucleus. Cell Proliferation, 39 (6) 519-35.
  • Dutton K, Dutton JR, Pauliny A and Kelsh RN. (2001) A morpholino phenocopy of the colourless mutant. Genesis. (3) 188-9
  • Ward A, Dutton JR. (1998) Regulation of the Wilms' tumour suppressor (WT1) gene by an antisense RNA: a link with genomic imprinting? J Pathology;185(4) 342-4
  • Dutton JR., Johns S. and B.L. Miller. (1997) StuA is a sequence specific transcription factor that regulates developmental complexity in Aspergillus nidulans. EMBO J 15; 5710-21